…
AOTI, Inc., together with its subsidiaries, produces, rents, and sells medical devices to resolve severe acute and chronic wounds for customers worldwide. The company offers topical wound oxygen solutions for use in the institutional and the home care settings to improve the health, well-being, and independence of patients; and NEXA, an negative pressure wound therapy system. AOTI, Inc. was incorporated in 2008 and is based in Oceanside, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.94M | -7.65M | 2.26M | -0.08M |
| Net income | -1.76M | -8.19M | 1.74M | -0.09M |
| Gross profit | 51.35M | 37.59M | 2.86M | 0.05M |
| Reconciled depreciation | 1.73M | 1.42M | 0.65M | 0.41M |
| Ebit | 0.91M | -5.70M | -0.07M | 3.49M |
| Ebitda | 2.64M | -4.28M | 0.48M | 3.58M |
| Depreciation and amortization | 1.73M | 1.42M | 0.55M | 0.09M |
| Operating income | 1.25M | -5.54M | 2.29M | -0.08M |
| Other operating expenses | 57.10M | 49.45M | 6.57M | 0.97M |
| Interest expense | 1.85M | 1.95M | 1.34M | 0.03M |
| Tax provision | 0.81M | 0.54M | 1.29M | 1.12M |
| Net interest income | -1.85M | -1.95M | -1.34M | -0.03M |
| Income tax expense | 0.81M | 0.54M | 0.52M | 0.00M |
| Total revenue | 58.36M | 43.92M | 8.86M | 0.89M |
| Total operating expenses | 50.10M | 43.13M | 0.57M | 0.12M |
| Cost of revenue | 7.00M | 6.32M | 6.00M | 0.84M |
| Total other income expense net | -2.20M | -2.11M | -1.34M | -0.04M |
| Net income from continuing ops | -1.76M | -8.19M | -2.80M | 2.03M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 39.54M | 21.08M | 9.35M | 1.51M |
| Intangible assets | 9.02M | 9.42M | 9.80M | 0.19M |
| Other current assets | 0.02M | 0.04M | 0.24M | 0.25M |
| Total liab | 22.10M | 26.99M | 5.94M | 1.25M |
| Total stockholder equity | 17.44M | -5.91M | 3.41M | 0.26M |
| Other current liab | 9.69M | 6.43M | 5.27M | -0.52M |
| Common stock | 0.00M | 0.00M | 2.16M | 0.35M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -17.65M | -15.89M | 1.25M | -0.10M |
| Other assets | - | - | 0.00M | - |
| Cash | 9.34M | 0.78M | 2.56M | 0.22M |
| Total current liabilities | 11.52M | 13.11M | 2.29M | 0.55M |
| Current deferred revenue | - | - | 0.52M | 0.00M |
| Net debt | -0.41M | 11.57M | 1.89M | 0.59M |
| Short term debt | 0.19M | 0.29M | 0.38M | 0.27M |
| Short long term debt | - | 0.00M | 0.20M | 0.23M |
| Short long term debt total | 8.92M | 12.35M | 4.45M | 0.81M |
| Other stockholder equity | 35.09M | 9.98M | 11.11M | 1.62M |
| Total current assets | 26.68M | 8.34M | 3.65M | 0.35M |
| Net receivables | 14.82M | 5.32M | 4.04M | 2.42M |
| Long term debt | 8.43M | 11.70M | 11.60M | 0.00M |
| Inventory | 2.51M | 2.20M | 0.27M | 0.03M |
| Accounts payable | 1.55M | 5.79M | 0.95M | 0.79M |
| Non currrent assets other | 0.03M | 0.03M | -9.80M | -0.19M |
| Non current assets total | 12.86M | 12.74M | 5.70M | 1.16M |
| Capital lease obligations | 0.49M | 0.66M | 0.61M | 0.04M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total cashflows from investing activities | -1.94M | -1.59M | -1.23M | -0.39M |
| Net borrowings | -4.00M | -0.20M | 11.55M | -0.69M |
| Total cash from financing activities | 16.41M | -0.20M | 0.65M | 0.49M |
| Net income | -1.76M | -8.19M | 1.74M | -0.09M |
| Change in cash | 8.56M | -3.24M | 2.34M | -1.09M |
| Begin period cash flow | 0.78M | 4.01M | 0.22M | 1.31M |
| End period cash flow | 9.34M | 0.78M | 2.56M | 0.22M |
| Total cash from operating activities | -5.91M | -1.45M | 2.77M | -0.05M |
| Issuance of capital stock | 24.73M | 0.00M | - | - |
| Depreciation | 1.73M | 1.42M | 0.55M | 0.09M |
| Other cashflows from investing activities | - | 0.87M | -0.23M | -0.01M |
| Dividends paid | - | 1.44M | 0.46M | - |
| Change to inventory | -0.31M | -0.23M | -0.12M | -0.03M |
| Change to account receivables | -10.00M | -1.03M | -0.54M | -0.09M |
| Other cashflows from financing activities | -4.33M | 1.44M | -0.14M | - |
| Capital expenditures | 1.94M | 1.32M | 1.00M | 0.38M |
| Change in working capital | -11.71M | 3.86M | -0.03M | -0.05M |
| Stock based compensation | 5.18M | 1.52M | 1.23M | 0.00M |
| Other non cash items | 0.64M | -0.05M | 1.64M | 0.24M |
| Free cash flow | -7.85M | -2.76M | 1.77M | -0.43M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AOTI AOTI Inc |
-1.00 0.77% |
129.00 | 18.25 | 8.10 | 0.64 | 2.76 | 0.94 | 8.31 |
| SN Smith & Nephew PLC |
-14.00 1.23% |
1122.50 | 23.24 | 12.47 | 1.70 | 2.59 | 2.67 | 10.76 |
| NIOX NIOX Group PLC |
2.00 2.99% |
69.00 | 28.20 | 18.73 | 4.84 | 3.41 | 4.35 | 13.85 |
| EKF EKF Diagnostics Holdings Plc |
-0.40 1.61% |
24.40 | - | 34.97 | 2.02 | 1.46 | 1.72 | 7.01 |
| CREO Creo Medical Group PLC |
- -% |
11.25 | - | - | 199.36 | 0.74 | 6.21 | 8.16 |
AOTI, Inc., together with its subsidiaries, produces, rents, and sells medical devices to resolve severe acute and chronic wounds for customers worldwide. The company offers topical wound oxygen solutions for use in the institutional and the home care settings to improve the health, well-being, and independence of patients; and NEXA, an negative pressure wound therapy system. AOTI, Inc. was incorporated in 2008 and is based in Oceanside, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael Griffiths CRT, DMS | President, CEO & Director | 1967 |
| Mr. Jayesh Pankhania | CFO & Director | 1970 |
| Mr. Darron Daly | Executive Vice President of Marketing & Professional Relations | NA |
| Ms. Gina So'oto | Executive Vice President of Global Human Resources | NA |
| Dr. Matthew G. Garoufalis CWS, DPM, FFPM | Chief Medical Officer | NA |
| Mr. David Hammond | President of Commercial International | NA |
| Mr. Marty Sylvain | Chief Advocacy Officer | NA |
| Ms. Stacy Reel | Chief Commercial Officer | NA |
| Mr. Robbie Walsh | Executive Vice President of Quality & Regulatory Affairs | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.